103
Participants
Start Date
August 15, 2023
Primary Completion Date
August 29, 2024
Study Completion Date
October 29, 2024
Placebo
Placebo will be administered intravenously.
Nipocalimab
Nipocalimab will be administered intravenously.
Certolizumab
Certolizumab will be administered subcutaneously.
Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula
Porcika Klinika - Vasarhelyi Sarkanyfu Kft., Hódmezővásárhely
CMed Rehabilitacios es Diagnosztikai Kozpont, Székesfehérvár
Vital Medical Center Orvosi es Fogaszati Kozpont, Veszprém
Altoona Center For Clinical Research, Duncansville
Hamburger Rheuma Forschungszentrum II, Hamburg
Atlanta Research Center for Rheumatology, Marietta
Integral Rheumatology And Immunology Specialists, Plantation
Bay Area Arthritis and Osteoporosis, Brandon
Clinical Research of West Florida, Clearwater
Rheumazentrum Ratingen, Ratingen
Graves Gilbert Clinic, Bowling Green
Rheumazentrum Ruhrgebiet, Herne
Southwest Rheumatology Research LLC, Mesquite
Arizona Arthritis and Rheumatology Research PLLC, Phoenix
Inland Rheumatology Clinical Trials Inc., Upland
Newport Huntington Medical Group, Huntington Beach
STAT Research S A, Buenos Aires
Centro Privado de Medicina Familiar, Buenos Aires
Sanatorio Agote, Buenos Aires
Hospital Central Militar Cirujano Mayor Dr Cosme Argerich, Buenos Aires
Mautalen Salud e Investigacion, CABA
ARCIS Salud SRL Aprillus asistencia e investigacion, CABA
Centro de Investigaciones Medicas Tucuman, San Miguel de Tucumán
Budai Irgalmasrendi Korhaz, Budapest
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz
NZOZ Lecznica MAK MED S C, Nadarzyn
MICS Centrum Medyczne Warszawa, Warsaw
Centrum Medyczne Reuma Park, Warsaw
Western General Hospital, Edinburgh
Medway NHS Foundation Trust, Gillingham
Kings College Hospital, London
Janssen Research & Development, LLC
INDUSTRY